A case of sarcomatoid carcinoma of the lung treated with a new radiopharmaceutical 225Ac-DOTA-IBA
DOTA-IBA is a novel bone-targeting precursor for metastatic bone disease. It was radiolabeled with 225Ac to generate the alpha-emitting therapeutic agent 225Ac-DOTA-IBA. In this report, a 70-year-old man with pulmonary sarcomatoid carcinoma and extensive skeletal metastases was treated upfront with 2 cycles of 225Ac-DOTA-IBA. The patient showed excellent symptomatic and radiological response. In addition, no adverse effects were observed in the patient.
Authors
- W Wang
- Chunmei Tian
- Yueqi Zhao
- Yue Chen
- Xiangting Liu
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Theranostics (New Zealand) (NZ)
- Molecular Theranostics (United States) (US)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1097/rlu.0000000000006234
- Primary Topic
- Metastasis and carcinoma case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00